Loading publications…
The last 5 uploaded publications
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR
Miguel Vizoso, Humberto J. Ferreira, Paula López-Serra, F. Javier Carmona, Anna Martínez‐Cardús, María Romina Girotti, Alberto Villanueva, Sònia Guil, Cátia Moutinho, Julia Liz, Anna Portela, Holger Heyn, Sebastián Morán, August Vidal, María Martínez‐Iniesta, José Luís Manzano, María Teresa Fernández‐Figueras, Elena Élez, Eva Muñoz‐Couselo, Rafael Botella‐Estrada, Alfonso Berrocal, Fredrik Pontén, Joost van den Oord, William M. Gallagher, Dennie T. Frederick, Keith T. Flaherty, Ultan McDermott, Paul Lorigan, Richard Marais, Manel Esteller (2015). Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. , 21(7), DOI: https://doi.org/10.1038/nm.3863.
Article74 days agoPrognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma
Emanuel Buehrer, Nina Glassée, Michal Kiciński, Oliver John Kennedy, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma. , DOI: https://doi.org/10.1016/j.ejcskn.2025.100727.
Article62 days agoThe role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Michielin Olivier, Reinhard Dummer, Paul Lorigan, Dirk Schadendorf, Georgina V. Long, Ester Simeone, Paolo A. Ascierto, Domenico Mallardo, Rachel Woodford, Alexander M. Menzies, Lisa Zimmer, A. P. Williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu (2023). The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. , 21(1), DOI: https://doi.org/10.1186/s12967-023-04607-4.
Article62 days agoAdjuvant therapy for stage II melanoma: the need for further studies
Rebecca Lee, Mario Mandalà, Georgina V. Long, Alexander M.M. Eggermont, Alexander C.J. van Akkooi, Shahneen Sandhu, Claus Garbe, Paul Lorigan (2023). Adjuvant therapy for stage II melanoma: the need for further studies. , 189, DOI: https://doi.org/10.1016/j.ejca.2023.05.003.
Article62 days agoPrognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassée, Michal Kiciński, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Emanuel Buhrer, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Mario Mandalà, Paul Lorigan, Sara Valpione (2024). Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. , 201, DOI: https://doi.org/10.1016/j.ejca.2024.113585.
Article62 days ago